D1 and D2 Dopamine Receptors in Gambling and Amphetamine Reinforcement (HFDEX)
Pathological Gambling
About this trial
This is an interventional diagnostic trial for Pathological Gambling focused on measuring amphetamine, d1 and d2 receptors, dopamine antagonists, pathological gambling, priming, reinforcement
Eligibility Criteria
Inclusion Criteria:
- PATHOLOGICAL GAMBLERS
- otherwise healthy, non-treatment seeking, non-abstinent
- male or female
- ages 19-65
- DSM-IV PG symptom scale score > 5
- SOGS (South Oaks Gambling Screen) score > 5
- nicotine dependence acceptable
- CONTROLS
- healthy
- male or female
- ages 19-65
- DSM-IV PG symptom scale score = 0
- SOGS score = 0
- nicotine dependence acceptable
- must have played slot machine > 5 times
Exclusion Criteria:
- both Pathological Gamblers and Controls
- Axis I psychopathology aside from nicotine dependence (or PG) based on SCID
- Schizotypal or Borderline Personality Disorder based on psychiatric interview
- Family history of schizophrenia or bipolar disorder
- English comprehension below grade 7 level.
- ADS (Alcohol Dependence Scale) > 13 (more than low dependence)
- BDI (Beck Depression Inventory) short form > 10 (more than low depression)
- DAST (Drug Abuse Screening Test) > 4 (possible drug abuse)
- Consumption of > 20/15 (men/women) standard alcoholic drinks/ week (hazardous drinking)
- Smoking > 20 cigarettes/day to help minimize withdrawal symptoms during test phase
- Any prior use of psychostimulant drugs
- Current use of medication that could interact with any of the study medications
- Women who are pregnant or breastfeeding
Sites / Locations
- Centre for Addiction and Mental Health
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Haloperidol
Fluphenazine
Subjects randomized to pre-treatment drug sequence 1 (haloperidol on day 1 of each phase), or drug sequence 2 (haloperidol on day 2 of each phase). Dose 1: 3 visually identical capsules, each containing 1 mg haloperidol OR 3 visually identical placebo (lactose) capsules Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 1 and 2 (Phase I), this will consist of 2 dummy capsules, visually identical to those administered for dose 1. On sessions 3 and 4 (Phase II), the dose will consist of 2 visually identical capsules each containing 10 mg dexedrine. Response measured to 15 min session of a commercial slot machine game.
Subjects randomized to pre-treatment drug sequence 1 (fluphenazine on day 1 of each phase), or drug sequence 2 (fluphenazine on day 2 of each phase). Dose 1: 3 visually identical capsules, each containing 1 mg fluphenazine OR 3 visually identical placebo (lactose) capsules Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 1 and 2 (Phase I), this will consist of 2 dummy capsules, visually identical to those administered for dose 1. On sessions 3 and 4 (Phase II), the dose will consist of 2 visually identical capsules each containing 10 mg dexedrine. Response measured to 15 min session of a commercial slot machine game.